



Fact Sheet for Molnupiravir: A Medicine for Treatment of COVID-19

(For Patients, Parents & Caregivers)

Q: What is Molnupiravir?

Molnupiravir is a medicine for treatment of mild-to-moderate COVID-19 disease. The U.S. Food and Drug Administration (FDA) first authorized its use in December 2021.

Q: Who can receive Molnupiravir?

Molnupiravir is for people with mild-to moderate symptoms of COVID-19 who:

- Are age 18 years and older,
- Have a positive COVID-19 test,
- Are at high risk for severe COVID-19, and
- Do not have access to other FDA-authorized treatment options.

Q: How is it administered?

Molnupiravir is taken by mouth. The usual dose is four tablets every 12 hours for five days. It is important to complete the full 5-day treatment course and continue isolation per public health recommendations. It should not be taken for more than five days.

Q: Who should NOT receive Molnupiravir?

Molnupiravir is NOT recommended for patients who are:

- Pregnant
- Breastfeeding
- Children

If you are pregnant or breastfeeding, consult with your healthcare provider before taking Molnupiravir. If you could become pregnant, use a reliable method of birth control if you will take this medicine. Continue it for at least three months after the last dose of Molnupiravir.

Q: What are possible side effects of Molnupiravir?

Side effects of this medicine include:

- Diarrhea
- Nausea
- Dizziness.





Q: What is Molnupiravir NOT used for?

Molnupiravir is NOT used for:

Initial treatment in patients needing hospitalization due to severe or critical COVID-19 disease

• Prevention of COVID-19 disease.

Q: Additional Information

If you have questions, please contact your healthcare provider, visit the Molnupiravir website at www.molnupiravir.com or call 1-800-672-6372.

